Every 10-Q that Kenvue Inc. (KVUE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KVUE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KVUE filings page.
Kenvue Inc., a global consumer health company, reported solid results for the fiscal three and six months ended June 28, 2026. Net sales were $3,955 million for the quarter and $7,864 million year-to-date, up from $3,839 million and $7,580 million in the prior-year periods. Quarterly net income was $456 million versus $420 million a year earlier, and year-to-date net income was $930 million versus $742 million. Diluted EPS was $0.24 for the quarter and $0.48 for six months.
Operating income reached $699 million in the quarter, with segment adjusted operating income of $512 million in Self Care, $186 million in Skin Health and Beauty, and $315 million in Essential Health. Operating cash flow for the first half was $1,177 million, against capital expenditures of $203 million, while total debt stood at $8,480 million and stockholders’ equity at $10,553 million as of June 28, 2026. The effective tax rate declined to 23.7% for the quarter, helped by a valuation allowance release and tax law effects. Kenvue also highlights a pending merger under which Kimberly-Clark will acquire all outstanding shares, with Kenvue shareholders to receive 0.14625 Kimberly-Clark shares plus $3.50 in cash per share and hold about 46% of the combined company, subject to remaining foreign regulatory approvals and other customary closing conditions. The company continues to monitor goodwill—particularly in Skin Health and Beauty—and discloses ongoing product liability and securities litigation without estimating possible losses beyond existing accruals.
Kenvue Inc. reported solid first-quarter 2026 results, with net sales of $3,909 million, up from $3,741 million a year earlier, and net income rising to $474 million from $322 million. Basic and diluted earnings per share increased to $0.25 from $0.17 as operating income improved to $767 million from $558 million, helped by lower selling, general, and administrative expenses.
Cash flow from operating activities strengthened to $489 million from $428 million, supporting dividends of $0.2075 per share, or $398 million in total. The company ended the quarter with $1,075 million in cash and cash equivalents and total debt of $8,661 million, including $7,072 million of long-term debt and $1,589 million of loans and notes payable.
Kenvue continues to execute its 2026 Restructuring Initiative, recording $78 million of related pre-tax charges in the quarter, mainly for employee-related and technology project costs. The company also advanced its pending acquisition by Kimberly-Clark, for which shareholders of both companies have approved the merger and key U.S. antitrust waiting periods have expired, while certain foreign regulatory approvals and customary closing conditions remain outstanding.
Kenvue Inc. (KVUE) reported Q3 fiscal 2025 results. Net sales were $3,764 million versus $3,899 million a year ago, with gross profit of $2,226 million. Operating income was $629 million, and net income reached $398 million, or $0.21 per diluted share. The company recorded $17 million of Separation-related costs in the quarter and paid a cash dividend of $0.2075 per share.
For the first nine months, net sales totaled $11,344 million and net income was $1,140 million. Cash flow from operations was $1,343 million. Total debt was $8,973 million, including commercial paper of $1,160 million; Kenvue issued $750 million of 4.85% Senior Notes due 2032 in May and the 5.50% Notes due 2025 were repaid. Shares outstanding were 1,915,802,170 as of October 28, 2025. Management noted the Skin Health and Beauty unit’s fair value exceeded carrying value by about 10% in Q3; a 100 bps higher discount rate would have resulted in an impairment.
Subsequent event: On November 2, 2025, Kenvue entered into a Merger Agreement with Kimberly‑Clark Corporation, subject to customary closing conditions and regulatory approvals.